Slope, the global leader in biospecimen lifecycle software, data, and services for the life sciences industry, and LabConnect, a premier provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services, announced the launch of their revolutionary bidirectional API integration, marking a historic first in the clinical trial industry.
This enhanced integration builds upon the existing collaboration between Slope and LabConnect, offering a more comprehensive and seamless connection between Slope’s Biospecimen360™ platform and LabConnect’s Laboratory Information Management System (LIMS).
The advanced integration goes far beyond traditional e-requisition solutions, enabling real-time, bidirectional data exchange. It encompasses all sample and subject metadata, as well as comprehensive kit and bulk supply inventory control from lab to site, at the site, and data-driven kit reordering back to LabConnect. This evolution represents a significant leap forward in biospecimen lifecycle management, addressing critical gaps in clinical trials and ensuring unprecedented levels of data integrity.
Also Read: Enveda Raises $130M for 10 Clinical Candidates
Key features of this groundbreaking integration include:
- Elimination of common accessioning errors associated with paper-based requisitions
- Removal of data discrepancies caused by duplicative data entry
- Eradication of data entry delays typically seen with lab-specific portal e-requisitions
- Complete control over kit inventory, sample metadata, and shipping processes
“This enhanced integration marks a significant advancement in biospecimen management,” said Rust Felix, CEO of Slope. “As part of our vendor-agnostic approach, Slope is committed to building an integrated lab ecosystem, with LabConnect as a key partner. This transformation sets a new standard for real-time data exchange in clinical trials, revolutionizing how the industry manages sample data and inventory.”
The Slope-LabConnect integration addresses a critical gap in clinical trials: ensuring the integrity of the sample itself. By providing real-time, error-free data exchange and inventory control, this solution significantly enhances the reliability of assay results.
Wes Wheeler, CEO of LabConnect, added, “The integrity of assay results begins with the integrity of the sample. Our integration with Slope ensures that every step of the biospecimen lifecycle is monitored, controlled, and documented with unparalleled accuracy. This level of data integrity has never before been achieved in our industry.”
The integration is now available to mutual clients of Slope and LabConnect, offering a unique opportunity to streamline operations, reduce errors, and accelerate research timelines.
SOURCE: PRNewswire